AUG 5·SEC EDGARLow
Morningside Venture Investments Ltd purchased $5.0M of APMD
Morningside Venture Investments Ltd purchased 312,500 shares of Apnimed, Inc. (APMD) at $16.00 ($5.00M total) on 2026-08-03.
StockNASDAQ · US · USDHealthcare · Biotechnology
$APMD
Apnimed, Inc.
Price · $APMDvia TradingView
AI sentiment · 7d2 articles
- Bullish
- 2
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- $5.2M 2 txs
- Sells
- — 6 txs
Miller Lawrence G.5× · —
10b5-1 plan0%
Top stories · $APMDMore →
AUG 3·investing.com
Apnimed raises $220.8M in upsized Nasdaq IPO
Apnimed, Inc. (Nasdaq: APMD) priced and closed an upsized Nasdaq IPO raising $220.8M in gross proceeds. It sold 13.8M shares at $16.00 each, including 1.8M from the underwriters’ overallotment option. Shares began trading July 31, 2026. The company develops AD109 for obstructive sleep apnea, with two Phase 3 trials completed and an NDA PDUFA goal date of Feb. 28, 2027.
AUG 3·SEC EDGAR
SEKHRI PAUL J purchased $200K of APMD
SEKHRI PAUL J purchased 12,500 shares of Apnimed, Inc. (APMD) at $16.00 ($0.20M total) on 2026-08-03.
APMD sentiment & insider activity
Over the past 7 days, alphai's AI scored 2 news stories mentioning APMD (Apnimed, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent APMD coverage spans ipo and insider activity.
In the last 30 days, APMD insiders filed 8 SEC Form 4 transactions — 2 purchases ($5.2M) and 6 sales. The most active reporter was Miller Lawrence G. with 5 filings.
What's driving APMD
This is a disclosed insider-style ownership increase by a large 10% holder, but it is not an executive transaction and lacks a 10b5-1 plan.
The IPO pricing and first trading details create an immediate supply and liquidity overhang, while the Phase 3 and NDA timeline provides a longer-dated catalyst path.
This is a disclosed insider open-market purchase, which can be read as modest bullish signaling but is not a fundamental catalyst by itself.
Fresh IPO pricing and first-day pop create immediate liquidity and sentiment-driven trading, while FDA review timing sets the next fundamental catalyst.
The IPO pricing and first-day pop create a near-term trading setup around liquidity, lockup expectations, and sentiment toward late-stage biotech demand.
alphai scores every news story that mentions APMD with an AI model for sentiment and relevance, and aggregates insider trades from Apnimed, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $APMD
Score
Morningside Venture Investments Ltd purchased $5.0M of APMD
Morningside Venture Investments Ltd purchased 312,500 shares of Apnimed, Inc. (APMD) at $16.00 ($5.00M total) on 2026-08-03.
2 min readApnimed raises $220.8M in upsized Nasdaq IPO
Apnimed, Inc. (Nasdaq: APMD) priced and closed an upsized Nasdaq IPO raising $220.8M in gross proceeds. It sold 13.8M shares at $16.00 each, including 1.8M from the underwriters’ overallotment option. Shares began trading July 31, 2026. The company develops AD109 for obstructive sleep apnea, with two Phase 3 trials completed and an NDA PDUFA goal date of Feb. 28, 2027.
2 min readSEKHRI PAUL J purchased $200K of APMD
SEKHRI PAUL J purchased 12,500 shares of Apnimed, Inc. (APMD) at $16.00 ($0.20M total) on 2026-08-03.
2 min readApnimed’s IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug - MedCity News
Apnimed raised $192M in its Nasdaq IPO, pricing 12M shares at $16 and debuting as APMD at $25, up 56% on the day. The company’s lead candidate Oxnimbi (formerly AD109) is under FDA review for obstructive sleep apnea. Apnimed submitted a new drug application in April; the FDA accepted it with a Feb. 28, 2027 decision date.
6 min read
Apnimed Soars 56% in Nasdaq Debut After $192M IPO
Apnimed Inc. (Nasdaq: APMD) jumped 56% in its Nasdaq debut after pricing an enlarged $192M IPO. It sold 12M shares at $14-$16, closing at $25. The company reported $84.8M revenue and $67.7M net income for the quarter ended March 31. It is developing Oxnimbi for obstructive sleep apnea, with an FDA marketing request filed in April.
5 min read
Apnimed Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- Apnimed, Inc. ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a price to the public of $16.00 per share.
2 min readApnimed prices IPO at $16 per share, raising $192 million
S. Korea’s KOSPI surges over 16% as Samsung, SK Hynix rebound after Wall St rally Apnimed, Inc., a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, has priced its initial public offering of 12 million shares of common stock at $16.00 per share, according to a press release issued July 30, 2026. The company expects to raise $192 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses.
4 min read
Apnimed sets $160m IPO for sleep apnea drug
Apnimed filed an S-1 for a US IPO of 10 million shares at $14 to $16, aiming to net about $134.6 million at the midpoint and about $155.5 million if underwriters exercise an option for 1.5 million more shares. The biotech’s lead drug Oxnimbi (AD109) targets obstructive sleep apnea; FDA accepted its NDA in July 2026 after two Phase III trials met primary endpoints.
4 min readApnimed scouts $160m IPO to back late-stage sleep apnoea pill development
Apnimed plans a Nasdaq IPO raising up to $160m, offering 10m shares at $14-$16 plus 1.5m additional shares. Funds will mainly support oxnimbi (AD109) for obstructive sleep apnoea, including FDA review of its Phase III data with an FDA decision expected by Feb 28, 2027. Ticker APMD.
5 min read